Genmab, a biotechnology company, showed robust performance in the stock market in 2025. Much of the company's positive momentum was driven by key achievements such as the acquisition of
Merus N.V. for
$8 billion, enhancing Genmab’s oncology portfolio significantly. This strategic acquisition was carried out successfully, following a tender offer for all issued and outstanding common shares of Merus, backed by
$2.5 billion debt-financed deal by Genmab. Stock market experts have viewed the company's move optimistically, leading to increased buy ratings by reputable market analysts including Leerink Partners, H.C. Wainwright, and Truist Securities. These institutions have further predicted a boost in Genmab stock, specifically citing promising data from clinical studies and FDA approval of its lymphoma drug,
Epkinly. These developments have attracted major interest from investment entities, with Marshall Wace LLP, First Trust Advisors LP and others increasing their stake in Genmab. Furthermore, the robust demand for
Darzalex has accelerated revenue growth for the company. However, despite the strong financial performance in Q3 2025, the Genmab stock dipped slightly, signaling market volatility.
Genmab Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 13 Dec 2025 19:55:21 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 6
